Naslov
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

Autori
Mocroft, A. ; Reiss, P. ; Rakhmanova, A. ; Banhegyi, D. ; Phillips, A.N. ; De Wit, S. ; Ristola, M. ; Lundgren, J.D. ; Grarup, J. ; Kirk, O. ; ... ; Begovac, Josip ; ...

Izvornik
Infection (0300-8126) 42 (2014), 4; 757-762

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
HIV ; Atripla ; Europe ; Viral load ; Antiretroviral therapy

Sažetak
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics ; 71.4 %), and least common in Eastern Europe (2/31 clinics ; 6.5 % ; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA